Is intercept pharmaceuticals inc going to be acquired_

Intercept Pharmaceuticals Inc. Noodles and company indonesian peanut saute ( NASDAQ:ICPT) diligently working on advanced treatments for liver disease, is searching for a potential buyer after giant pharmaceutical companies showed interest, as per the sources familiar with the matter.

The sources said that the company is talking to investment bankers to look for more prospects of a sale. Noodles and company salads They are hesitant to give any confirmation in relation to the certainty of the news.


Noodles and company vernon hills On the other hand, the company has declined to comment on the news as well. Hours for noodles and company The news directly affected the company stock, which resulted in a surge of 37% at $120.22 at market close on Friday.

The biotechnology company’s stock has also been oppressed to a significant degree by broader market forces acting on the biotechnology sector, including US Presidential candidate Hillary Clinton’s comments on drug pricing.

It is one of the leading companies playing their role in the research and development of drug for the treatment of nonalcoholic steatohepatitis (NASH). Noodles n company Other notable companies include French biotech Genfit, who had started enrolling patients in a Phase III trial for NASH, while Gilead Sciences, Inc. Noodles and company 29th street ( NASDAQ:GILD), Enanta Pharmaceuticals Inc. Noodles and company jacksonville (Nasdaq:ENTA), and Shire PLC (ADR) ( NASDAQ:SHPG) have their own molecules. Noodles and company stapleton RUMORS

A week ago, rumors widespread regarding a potential merger of Intercept and Shire. Noodles and company denver Keeping in view Shire’s interest in Baxalta (NYSE: BXLT), the majority of the market observers think that the British drug maker will not take keen interest in acquiring Intercept.

One rumor suggests that Intercept hired CenterView Partners for the exploration of a potential suitor. When does noodles and company close Centerview Partners was the key player in the Dyax-Shire merger transaction and Celgene Corporation (NASDAQ:CELG)’s acquisition of Receptos. Noodles and company york pa EXPECTED POTENTIAL BUYERS

The expected buyers list includes Gilead Sciences, Shire, Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), and Merck (MRK). Noodles and company minneapolis WHY GILEAD OR SHIRE

Both the companies are the strongest candidate for the acquisition of Intercept. Noodles and company menu gluten free Gilead is the market leader for the hepatitis C virus in the therapeutic market with its drugs Sovaldi and Harvoni. Noodles and companh The market is now getting saturated with the introduction of a new drug by Merck, Zepatier, which is very cost effective and shows the same level of efficacy and safety when compared to Sovaldi and Harvoni. Noodles and company menu pdf Last December, the company’s management said while talking to Financial Times that the drug maker is looking for a potential merger or acquisition to expand the therapeutic area as well as to cover up the revenue gap. Food with noodles The financial position of the company is very strong and it can carry out one or more acquisitions. Noodles and company yorktown With the acquisition, Gilead will also acquire Intercept’s NASH program as it has vast experience in the segment of liver diseases treatment. Where are noodles from The drug maker has also jumped in the oncology profile last year with five oncology molecules going through Phase 3, two in Phase 2, and three in the starting phases.

On the other hand, Shire has acquired Lumena Pharmaceuticals in May, 2015. Noodles plus menu The drug company brought two novel, highly potent, and selective inhibitors of the apical sodium-dependent bile acid transporter, SHP625 and LUM002 (SHP626). Noodles and company boise SHP626 is related to the treatment of NASH. Noodles and company yelp SHP625 is going through Phase 2 trials for four orphan disease indications.

Shire has a healthy cash flow and would be able to pay the debt in the next few years. Noodles menu calories Intercept’s take over by Shire will make the lateral’s portfolio more productive with the addition of NASH portfolio. Noodles and company 76th st FDA APPROVAL

In December 2015, the US Food and Drug Administration (FDA) postponed its decision by three months on Intercept’s marketing application for its main drug. Noodles and company prices The regulatory agency had set a deadline initially on February 29, 2016, to take a final decision for the approval of its obeticholic acid (OCA) for the treatment of primary biliary cirrhosis (PBC). Noodles and company delivery In case of approval, the company is expecting a revenue generation of $2.62 billion by 2020.

Obeticholic acid is also undergoing trials for the treatment of nonalcoholic steatohepatitis (NASH), which is a very big market. Noodles king menu There are also some issues during the trials regarding the safety and efficacy profile of the drug. Noodles and company laurel DRUG PIPELINE

Intercept is the pioneer in the use of FXR agonism, which plays a vital role as a potential catalyst in anticholestatic and antifibrotic mechanisms.

Its drug pipeline is robust and very competitive, which includes obeticholic acid for the treatment of primary biliary cirrhosis (PBC) in the filling process, the drug is undergoing clinical trial for nonalcoholic steatohepatitis (NASH) primary sclerosing cholangitis (PSC), and biliary atresia. Noodles and company east lansing In addition INT-767 (FXR/TGRS Agonist) for fibrosis and INT-777 (TGRS agonist) for type-2 diabetes are in Phase 1. Noodles and company workday ANALYSTS’ VIEW

RBC Capital Markets analyst Michael Yee wrote: “We doubt that Intercept could or would be acquired before at least an adcom panel to discuss the risk/benefit of the drug for PBC approval, and any indications of interest by an acquirer would be more to just do due diligence and explore scenarios and valuations first.”

The Street Quant Rating has given the company a Sell rating. Noodles and company zona rosa The main reason for the Sell rating is the company’s weakness and lacking growth in net income, weak operating cash flow, overall disappointing historical performance in the stock itself, and feeble growth in its earnings per share.

According to Stockz Intelligence Inc., Out of 14 analysts covering Intercept, 11 has given the rating of a Buy, two of Sell, and the remaining three of Hold.

Zacks Investment Research upgraded shares from a Hold rating to a Buy rating with a setting of $186.00 as a price target in a research note on Wednesday, October 7, 2015.